Relevant clinical trials demonstrating efficacy of immune checkpoint inhibitors and BRAF kinase inhibitors and MEK kinase inhibitors (BRAF/MEK inhibitors) in unresectable/metastatic melanoma. This evidence concerns the gene BRAF and metastatic melanoma.